Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Comprehensive Overview
Published in JAMA Psychiatry in 2020, this study asked whether psilocybin, the active compound in psychedelic mushrooms, paired with supportive psychotherapy could effectively treat major depressive disorder in the general population of people with the condition, extending earlier evidence that had been limited to cancer patients and those with treatment-resistant depression. Researchers at Johns Hopkins conducted a randomized, waiting-list-controlled clinical trial enrolling 27 adults ages 21 to 75 with a diagnosed depressive episode who were not currently using antidepressant medication and had no history of psychotic disorder or serious suicide attempt. Participants were randomly assigned to receive two psilocybin sessions, roughly a week and a half apart, embedded within about 11 hours of supportive psychotherapy, either immediately or after an 8-week waiting period that served as the control condition. The primary outcome was depression severity, measured with the clinician-administered GRID-Hamilton Depression Rating Scale, compared between the immediate-treatment group at weeks 1 and 4 after their second session and the delayed-treatment group at the equivalent waiting-period time points. The topline result was that psilocybin therapy produced a large, rapid, and sustained reduction in depression severity, with effect sizes considerably larger than those typically reported for either psychotherapy or antidepressant medication alone.
Outcomes and Implications
The most important finding was that participants who received immediate psilocybin therapy had significantly lower depression scores at weeks 1 and 4 after their sessions than participants in the delayed-treatment group had at the matched time points before receiving therapy, with very large effect sizes at both week 1 and week 4 comparisons. In the full sample of 24 participants who completed treatment, 71% showed a clinically significant response, defined as at least a 50% reduction in depression severity, at both the 1-week and 4-week follow-up assessments, and roughly half were in full remission by week 4. A secondary self-report measure showed an especially striking pattern: depression scores dropped substantially just one day after the first psilocybin session, and this rapid improvement was sustained through the 4-week follow-up. Anxiety symptoms improved alongside depression, and participants who described their psilocybin sessions as more mystical or personally meaningful tended to show larger reductions in depression. No serious adverse events occurred; the main side effects were transient headache and difficult emotions such as fear or sadness during dosing sessions, and one participant needed brief monitoring for a temporary blood pressure spike that resolved on its own. The authors conclude that psilocybin-assisted therapy produced large, rapid, durable antidepressant effects in this population, extending findings previously limited to cancer patients and treatment-resistant cases, though they caution that the small, largely White sample and short follow-up mean larger, more diverse, placebo-controlled trials are still needed.